Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.21 USD | +0.86% | +8.16% | +11.50% |
07/05 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
07/05 | (HALO) HALOZYME THERAPEUTICS Sees Fiscal Year 2024 Revenue Range $915M - $985M | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.50% | 5.19B | |
+10.44% | 106B | |
+0.82% | 104B | |
+6.72% | 23.25B | |
-13.89% | 22.5B | |
-6.64% | 18.7B | |
-37.26% | 17.95B | |
-10.98% | 16.99B | |
+8.67% | 14.26B | |
+41.08% | 12.76B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Earnings Flash (HALO) HALOZYME THERAPEUTICS Posts Q2 EPS $0.53